Cargando…

Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review

Cholangiocarcinoma is an uncommon gastrointestinal neoplasm characterized by the abnormal proliferation of cholangiocytes within the biliary duct. This type of malignancy can be subdivided into three major classes: intrahepatic cholangiocarcinoma (iCCA), perihilar cholangiocarcinoma (pCCA), and dist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sumbly, Vikram, Landry, Ian, Rizzo, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Gastroenterology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818329/ https://www.ncbi.nlm.nih.gov/pubmed/35154988 http://dx.doi.org/10.7759/cureus.21018

Ejemplares similares

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2023)

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
por: Cleary, James M., et al.
Publicado: (2022)

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
por: Popovici-Muller, Janeta, et al.
Publicado: (2018)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
por: Vo, Anh Huan, et al.
Publicado: (2022)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
por: Jiang, Xuemin, et al.
Publicado: (2021)

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
por: Dinardo, Courtney, et al.
Publicado: (2023)

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2023)

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study
por: Tejera, Dalissa, et al.
Publicado: (2020)

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
por: Fan, Bin, et al.
Publicado: (2019)

Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
por: Rimini, Margherita, et al.
Publicado: (2023)

Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature
por: Landry, Ian, et al.
Publicado: (2022)

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial
por: Zhu, Andrew X., et al.
Publicado: (2021)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

Associations of Liver Fluke Infection and Cholangiocarcinoma: A Scoping Review
por: Sivanand, Ankitha, et al.
Publicado: (2023)

A Unique Case of Gallbladder Agenesis and Cholangiocarcinoma
por: Tagliaferri, Ariana R, et al.
Publicado: (2023)

Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer
por: Sumbly, Vikram, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
por: Fan, Bin, et al.
Publicado: (2022)

A Patient’s Journey With Rare Biphenotypic Hepatocellular Carcinoma and Cholangiocarcinoma
por: Gersowsky, Danny B, et al.
Publicado: (2020)

A Case of Advanced Multifocal Cholangiocarcinoma With Excellent Response to Pembrolizumab
por: Habib, Tehmina, et al.
Publicado: (2023)

Pathological Clavicle Fracture: Initial Presentation of Intrahepatic Cholangiocarcinoma
por: Başdelioğlu, Koray
Publicado: (2020)

Primary Combined Hepatocellular-Cholangiocarcinoma: A Case of Underdiagnosed Primary Liver Cancer
por: Ayas, Mohamad F, et al.
Publicado: (2021)

Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2018)

Intrahepatic Cholangiocarcinoma With Lung Metastasis in a 29-Year-Old Male Patient: A Case Report
por: Calle Prado, Marco A, et al.
Publicado: (2023)

Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review
por: Gopalan, Sarath, et al.
Publicado: (2023)

Large-Cell Esophageal Neuroendocrine Tumor Leading to Hepatorenal Syndrome
por: Umar, Zaryab, et al.
Publicado: (2022)

Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden
por: Abudalou, Mohammad, et al.
Publicado: (2021)

Use of Balloon Occluded Retrograde Transvenous Obliteration (BRTO) for Treatment of Gastric Varices: A Narrative Review
por: Khakwani, Anum, et al.
Publicado: (2023)

Viral Hepatitis as a Public Health Concern: A Narrative Review About the Current Scenario and the Way Forward
por: Bhadoria, Ajeet S, et al.
Publicado: (2022)

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
por: Farshidfar, Farshad, et al.
Publicado: (2017)

Leukemic stem cells and advances in hematopoietic stem cell transplantation for acute myeloid leukemia: a narrative review of clinical trials
por: Sumbly, Vikram, et al.
Publicado: (2022)

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors
por: Reinbold, Raphael, et al.
Publicado: (2022)

Correction to: Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2019)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Aggressive Natural Killer Cell Leukemia: A Brief Overview of Its Genomic Landscape, Histological Features, and Current Management
por: Sumbly, Vikram, et al.
Publicado: (2022)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
por: Wang, Yuxiang, et al.
Publicado: (2020)

The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma
por: Yu, Hua, et al.
Publicado: (2020)

Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
por: Jiang, Jing-Hua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_um0qu0asiq4i5ocu87717l2ab9